Academician Sergei, former Deputy Prime Minister of Ukraine and Ukraine’s leading immunology expert, along with his delegation, paid a visit to Minhai to conduct an inspection and provide guidance.

Release date:

2023-05-22

Author:

Source:


Abstract

On May 18, 2023, a delegation of experts—including Sergey Vasilyevich Komissarenko, former Deputy Prime Minister of Ukraine, Ukraine’s leading immunology expert (and Chair of the Biosecurity Subcommittee of the National Security and Defense Council), recipient of China’s Friendship Award, and Director of the Department of Medical Biology at the National Academy of Sciences of Ukraine—visited our company for an inspection, exchange, and guidance. Zhang Qian, General Manager of the International Business Division, along with other company leaders, hosted the delegation, and relevant personnel from the International Business Division attended the meeting. Zhang Qian briefed Academician Sergey and his team on Kangtai (Minhai)’s development history, factory facilities, product portfolio, R&D and sales operations, and international market expansion, adding that Kangtai has consistently focused on vaccines…

On May 18, 2023, a delegation of experts—including Serhiy Vasyliovych Komysarionko, former Deputy Prime Minister of Ukraine, Ukraine’s leading immunology expert (and Chair of the Biosecurity Subcommittee of the National Security and Defense Council), recipient of the Chinese Friendship Award, and Director of the Department of Medical Biology at the National Academy of Sciences of Ukraine—visited our company for an inspection, exchange, and guidance session. Zhang Qian, General Manager of the International Business Division, along with other company leaders, accompanied the delegation, and relevant personnel from the International Business Division attended the meeting.

Zhang Qian briefed Academician Sergei and his delegation on Kangtai (Minhai)’s development history, its manufacturing facilities, product portfolio, R&D and sales operations, and international market expansion. He stated that Kangtai has consistently focused on the research, development, production, and commercialization of vaccines. Several of Kangtai’s products have been included in major national projects, including the 13-valent pneumococcal conjugate vaccine, inactivated poliovirus vaccine, and a quadrivalent combination vaccine. Currently, Kangtai is intensifying its efforts to expand into overseas markets, with the hope of collaborating with Ukraine’s Ministry of Health across multiple dimensions to penetrate Ukraine’s routine immunization market and contribute to global public health.

Academician Sergei outlined his work in Ukraine’s biotechnology sector and his research in the mRNA and CHO‑cell platforms, expressing readiness to strengthen collaboration with CanSino on the development of mRNA vaccines and CHO‑cell platforms. Following this, Academician Sergei and other experts visited Minhai Biologics’ state-of-the-art, internationally‑oriented vaccine industrial base for an on-site inspection and took a commemorative group photo.

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09